EB

BPGbio Appoints Ritesh Srivastava as General Counsel

Retrieved on: 
Monday, January 22, 2024

BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.

Key Points: 
  • BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.
  • Mr. Srivastava joins BPGbio from Spectrum Pharmaceuticals, a publicly traded biopharmaceutical company, where he held several leadership roles for over five years, including most recently as Global Compliance Officer.
  • At Spectrum, Mr. Srivastava provided leadership and counsel in all legal and compliance matters in acquiring, developing, and commercializing novel and targeted drug products in hematology and oncology.
  • “Ritesh Srivastava is a proven leader in the biopharma industry and a skilled corporate counsel,” said Niven R. Narain , Ph.D., CEO and President of BPGbio.

LIFT Intersects 27 m at 1.26% Li2O and 22 m at 1.53% Li2O at its Fi Main pegmatite, Yellowknife Lithium Project, NWT

Retrieved on: 
Tuesday, January 16, 2024

The Fi Main pegmatite comprises a 10-100 m wide corridor of 1-5 dykes that dip between 70°-85° to the west-northwest and extends for at least 1,500 m on surface.

Key Points: 
  • The Fi Main pegmatite comprises a 10-100 m wide corridor of 1-5 dykes that dip between 70°-85° to the west-northwest and extends for at least 1,500 m on surface.
  • YLP-0141 tested the Fi Main pegmatite approximately 400 m from its northern mapped extent and 50 m vertically beneath the surface.
  • Figure 3 – Cross-section illustrating YLP-0141 with results as shown in the Fi Main pegmatite dyke with a 27 m interval of 1.26% Li2O.
  • Figure 4 – Cross-section illustrating YLP-0147 with results as shown in the Fi Main pegmatite dyke with a 22 m interval of 1.53% Li2O.

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa

Retrieved on: 
Tuesday, December 19, 2023

BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of EB with blisters beginning in infancy. FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January of this year.

Key Points: 
  • FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of EB with blisters beginning in infancy.
  • FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January of this year.
  • "At Chiesi Global Rare Diseases we are driven by a need to alleviate the burdens faced in the rare disease community by providing innovative therapies and solutions that address debilitating unmet needs.” Giacomo Chiesi, Head of Chiesi Global Rare Diseases, said.
  • FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Retrieved on: 
Monday, November 13, 2023

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter of 2023 and provided corporate updates.

Key Points: 
  • The FDA also agreed that retroviral vector manufactured at Abeona and Indiana University appear comparable based on the data that Abeona provided in its briefing book.
  • If accepted with Priority Review, Abeona expects potential BLA approval in the second quarter of 2024.
  • Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.
  • Abeona Therapeutics will host a conference call and webcast today, November 13, 2023, at 8:30 a.m.

Patra Accelerates International Expansion Into Canada

Retrieved on: 
Wednesday, November 29, 2023

Patra, a leading provider of technology-enabled insurance outsourcing services, is delighted to announce its expansion into the Canadian market.

Key Points: 
  • Patra, a leading provider of technology-enabled insurance outsourcing services, is delighted to announce its expansion into the Canadian market.
  • The expansion into Canada marks a significant step in Patra’s global expansion plans to offer comprehensive and unique insurance service offerings to the Canadian market.
  • “Canada is a natural market expansion for Patra with an initial set of customers already established.
  • Sharon brings decades of Canadian insurance experience to market, most recently with Trufla Technology, Apollo Insurance, and First Insurance Funding of Canada.

Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors

Retrieved on: 
Monday, November 13, 2023

BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.

Key Points: 
  • BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.
  • “We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott , Executive Chairman of BPGbio.
  • He has served as a director of, and advisor to, several healthcare and technology companies.
  • He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).

Elektrobit to Showcase 360° Offering for Software-Defined Mobility at CES 2024

Retrieved on: 
Monday, December 11, 2023

ERLANGEN, Germany, Dec. 11, 2023 /PRNewswire/ -- At CES 2024,  Elektrobit will showcase its 360° offering for software-defined vehicle (SDV) enablement, from automotive architecture and virtual development solutions to leading-edge digital cockpits that provide the ultimate in-vehicle user experiences. The company's innovative software and services—reflecting decades of experience and spanning a wide range of solutions road-tested in more than 600 million vehicles and over 5 billion embedded devices—allow carmakers to accelerate the development of their next-generation vehicles.

Key Points: 
  • "Our goal is to make it easier for carmakers to develop the complex systems that are required for software-defined mobility.
  • Elektrobit software and services have helped carmakers—including industry newcomer Sony Honda Mobility with its AFEELA prototype—realize their visions.
  • during the CES Research Summit, Jan. 8, 2024, 3:00 pm PST at LVCC West, Level 2, W232.
  • To learn more or schedule a demonstration with Elektrobit at CES 2024, email [email protected] .

BLUETTI Introduces Reliable Power Solutions to Ukraine

Retrieved on: 
Monday, November 27, 2023

STUHR, Germany, Nov. 27, 2023 /PRNewswire/ -- BLUETTI , a leading power solution brand, has made a strategic market entry into Ukraine by offering several convenient power stations on its new Ukrainian website to power households through possible blackouts.

Key Points: 
  • STUHR, Germany, Nov. 27, 2023 /PRNewswire/ -- BLUETTI , a leading power solution brand, has made a strategic market entry into Ukraine by offering several convenient power stations on its new Ukrainian website to power households through possible blackouts.
  • For emergency power needs, BLUETTI offers the EB series grab-and-go generators, with the EB3A weighing only 4,6kg.
  • For prolonged power outages, BLUETTI's AC300 and AC500 modular power stations serve as perfect uninterrupted power sources.
  • This easy-to-install system provides 6.000 watts and a substantial 19,8kWh capacity, ensuring reliable home backup power.

EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research

Retrieved on: 
Tuesday, November 14, 2023

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Eddie Vedder played two intimate concerts in his hometown of Seattle at Benaroya Hall on October 23rd and 24th to bring support to a cause that is near to his heart – EB Research Partnership (EBRP). Alongside the emotional shows, EBRP hosted its first in-person Venture Into Cures Summit and Dinner.

Key Points: 
  • EB Research Partnership hosted the Venture Into Cures Summit alongside two Eddie Vedder shows in Seattle to support their mission of curing EB and other rare diseases.
  • EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research.
  • Founded in 2010 by a group of dedicated parents, Jill Vedder, and Eddie Vedder of Pearl Jam, EB Research Partnership (EBRP) is the largest 501(c)(3) nonprofit funding research aimed at finding a cure for Epidermolysis Bullosa (EB).
  • We can make an impact for the millions out there battling a rare disease," said Jill Vedder, Co-Founder and Chairwoman at EBRP.

debra of America Raises $600,000 at Annual Benefit; Honors Trailblazers in Epidermolysis Bullosa Community

Retrieved on: 
Friday, November 10, 2023

Funds raised help advance EB research initiatives and directly support families and individuals living with EB.

Key Points: 
  • Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
  • At the benefit, debra honored several EB trailblazers for their research and therapeutic contributions as well as individuals living with the disease.
  • Krystal Biotech was recognized for its work in developing VYJUVEK™ (beremagene geperpavec-svdt), the first FDA-approved treatment of Dystrophic Epidermolysis Bullosa (DEB).
  • Epidermolysis Bullosa is a rare genetic disorder characterized by fragile skin that easily blisters or forms painful sores from minor friction or trauma.